Skip to main content
海尔施 logo

海尔施 — Investor Relations & Filings

Ticker · 601206 Shanghai Stock Exchange Human health and social work activities
Open in API
Filings indexed 6 across all filing types
Latest filing 2016-08-16 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 601206

About 海尔施

https://www.nb-health.com/

Ningbo Haershi Pharmaceutical Co., Ltd. specializes in the research, development, and distribution of in vitro diagnostic products and pharmaceutical supplies. The organization provides a broad spectrum of diagnostic reagents, laboratory instrumentation, and clinical testing services. It serves as a strategic partner for global medical technology brands, facilitating the integration of advanced diagnostic solutions into clinical workflows. The company’s core activities include the supply of biochemical, immunological, and molecular diagnostic tools designed to support healthcare providers in accurate disease detection and monitoring. Through its comprehensive logistics and technical service network, the entity ensures the reliable delivery and maintenance of critical medical equipment and consumables for hospitals and laboratories.

Recent filings

Filing Released Lang Actions
首次公开发行A股暂缓发行的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the suspension of the initial public offering (IPO) process of Haier Sh Biopharmaceutical Co., Ltd. It mentions the approval from the China Securities Regulatory Commission, the planned issuance of shares, and the decision to delay the issuance due to media concerns. The document is a formal notice about the postponement of the IPO activities and does not contain financial statements, detailed financial data, or a full report. It is not an annual report, earnings release, or any detailed financial filing. It is also not a regulatory certification or officer attestation. The content fits best into the category of Capital/Financing Update (CAP) because it relates to the company's fundraising and capital issuance activities and provides an update on the status of the IPO process.
2016-08-16 Chinese
首次公开发行股票网上路演公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the online roadshow for the initial public offering (IPO) of Haier Sh Biopharmaceutical Co., Ltd. It details the offering size, pricing mechanism, and the schedule for the online roadshow event. It does not contain financial statements or detailed financial data but serves as an informational notice to investors about the IPO process and related events. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities such as IPOs.
2016-08-15 Chinese
首次公开发行股票招股意向书附录
Regulatory Filings
2016-08-09 Chinese
首次公开发行股票招股意向书摘要
Regulatory Filings Classification · 95% confidence The document is titled as a "首次公开发行股票招股意向书摘要" which translates to "Summary of Prospectus for Initial Public Offering (IPO)". It contains detailed information about the IPO, including share lock-up commitments, risk factors, issuance details, shareholder commitments, and dividend policies. It is not a financial report like an annual or interim report, nor is it an earnings release or a call transcript. It is a regulatory filing related to the IPO process, specifically a prospectus summary. Given the detailed nature and regulatory context, but not fitting into other specific categories, this document is best classified under Regulatory Filings (RNS).
2016-08-09 Chinese
首次公开发行股票招股意向书
Capital/Financing Update Classification · 95% confidence The document is titled as a 招股意向书, which translates to a "Prospectus" or "Offering Intention Document" for an initial public offering (IPO). It contains detailed information about the company's stock issuance, shareholder commitments, lock-up periods, dividend policies, risk factors, and other disclosures typical of an IPO prospectus. It is not an annual report, earnings release, or any other financial report type. It is also not a simple announcement or regulatory filing but a comprehensive document related to the company's capital raising and stock issuance. According to the filing definitions, this type of document corresponds to a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities, including IPO prospectuses and related disclosures.
2016-08-09 Chinese
首次公开发行股票发行安排及初步询价公告
Capital/Financing Update Classification · 95% confidence The document is titled "首次公开发行股票发行安排及初步询价公告" which translates to "Initial Public Offering (IPO) Issuance Arrangement and Preliminary Inquiry Announcement". It details the procedures, conditions, and schedules for the IPO of Haier Biomedical Pharmaceutical Co., Ltd., including pricing, investor eligibility, subscription process, and underwriting arrangements. It references regulatory approvals from the China Securities Regulatory Commission and specific regulatory rules governing IPOs. The document is an announcement related to the IPO issuance process and preliminary pricing inquiry, not a financial report or earnings release. It is not a full financial report, audit, or management discussion, but rather a detailed announcement about the capital raising process and issuance arrangements. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2016-08-09 Chinese

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.